These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37952844)

  • 21. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
    Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
    J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.
    Estroff JM; Devlin J; Hoteit L; Hassoune A; Neal MD; Brown JB; Lu L; Kotch S; Hazelton JP; Christian AB; Yeates EO; Nahmias J; Jacobson LE; Williams J; Schuster KM; O'Connor R; Semon GR; Straughn AD; Cullinane D; Egodage T; Kincaid M; Rollins A; Amdur R; Sarani B
    J Trauma Acute Care Surg; 2024 Oct; 97(4):541-545. PubMed ID: 38685190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings.
    Hitchcock ZR; Smith SD; Le LT; Lees LR; Brandt MD
    J Pharm Pract; 2023 Apr; 36(2):221-226. PubMed ID: 34231410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis.
    Luo C; Chen F; Chen YH; Zhao CF; Feng CZ; Liu HX; Luo DZQ
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2637-2653. PubMed ID: 33829451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
    Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
    Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series.
    Bradshaw PG; Keegan S; Foertsch M; Yang GL; Ngwenya LB; Srinivasan V
    J Thromb Thrombolysis; 2022 Aug; 54(2):295-300. PubMed ID: 35507109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis.
    Shrestha DB; Budhathoki P; Adhikari A; Shrestha S; Khati N; Mir WAY; Joshi T; Shrestha A
    Cureus; 2021 Dec; 13(12):e20632. PubMed ID: 35103198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
    Reynolds TR; Gilbert BW; Hall KM
    J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
    Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
    Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
    Chaudhary R; Singh A; Chaudhary R; Bashline M; Houghton DE; Rabinstein A; Adamski J; Arndt R; Ou NN; Rudis MI; Brown CS; Wieruszewski ED; Wanek M; Brinkman NJ; Linderbaum JA; Sorenson MA; Atkinson JL; Thompson KM; Aiyer AN; McBane RD
    JAMA Netw Open; 2022 Nov; 5(11):e2240145. PubMed ID: 36331504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
    Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
    Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-administration of Four-Factor Prothrombin Complex Concentrate With Andexanet alfa for Reversal of Nontraumatic Intracranial Hemorrhage.
    Pathan S
    Hosp Pharm; 2024 Aug; 59(4):394-406. PubMed ID: 38919755
    [No Abstract]   [Full Text] [Related]  

  • 34. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
    Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW
    Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
    Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
    Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study.
    Singer AJ; Concha M; Williams J; Brown CS; Fernandes R; Thode HC; Kirchman M; Rabinstein AA
    West J Emerg Med; 2023 Sep; 24(5):939-949. PubMed ID: 37788035
    [No Abstract]   [Full Text] [Related]  

  • 37. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
    Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW
    J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review.
    Phillips A; Bradley C; Cash J; Sangiovanni R; Wingerson C
    Am J Health Syst Pharm; 2024 May; 81(11):e274-e282. PubMed ID: 38430127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.